Trial Profile
A Double-Blind, Multicenter, Randomized, Titrated-Dose, Placebo-Controlled, Study of MK0364 (4 mg to 8 mg) in Chronic Cigarette Smokers as an Aid for Smoking Cessation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 May 2022
Price :
$35
*
At a glance
- Drugs Taranabant (Primary)
- Indications Smoking withdrawal
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 13 Nov 2013 New trial record